SEARCH:   Advanced

Blood, 15 September 2004, Vol. 104, No. 6, pp. 1631-1638. Prepublished online as a Blood First Edition Paper on July 8, 2004; DOI 10.1182/blood-2004-01-0360. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-01-0360v1 2004-01-0360v2 104/6/1631    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dummer, R. Articles by Urosevic, M. Search for Related Content PubMed PubMed Citation Articles by Dummer, R. Articles by Urosevic, M. Related Collections Immunobiology Immunotherapy Clinical Trials and Observations Gene Therapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  GENE THERAPY Adenovirus-mediated intralesional interferon- gene transfer induces tumor regressions in cutaneous lymphomas Reinhard Dummer, Jessica C. Hassel, Friederike Fellenberg, Stefan Eichmüller, Tanja Maier, Philippe Slos, Bruce Acres, Pascal Bleuzen, Vincent Bataille, Patrick Squiban, Günter Burg, and Mirjana Urosevic From the Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany; and Transgene SA, Strasbourg, France. Primary cutaneous lymphomas have been successfully treated with interferons (IFNs), counterbalancing the T-helper 2 (Th2)-skewing state. We undertook a phase 1, open-label, dose-escalating trial of repeated intratumoral administration of TG1042 in patients with advanced primary cutaneous T-cell lymphomas (CTCLs) and multilesional cutaneous B-cell lymphomas (CBCLs). TG1042 is a third-generation, nonreplicating human adenovirus vector containing a human IFN- cDNA insert. Nine patients (7 CTCL, 2 CBCL) were enrolled at the following TG1042 doses: 3 x 109, 3 x 1010, and 3 x 1011 total particles. Local clinical response was observed in 5 of 9 treated patients (3 patients with complete response [CR] and 2 patients with partial response [PR]). Out of these, 3 patients showed systemic CR with the clearance of other noninjected skin lesions. Clinical response lasted for a median of 3 months (range, 1-6 months). Adverse events were mostly of grades 1 and 2. Seven of 9 treated patients had a detectable TG1042-derived IFN- message in injected lesions after the first treatment cycle. A TG1042-IFN- message was also detectable after several treatment cycles. We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated. (Blood. 2004;104:1631-1638) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al. Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase Cancer Res., April 1, 2009; 69(7): 3228 - 3237. [Abstract] [Full Text] [PDF] D. J. Casso, S. Liu, D. D. Iwaki, S. K. Ogden, and T. B. Kornberg A Screen for Modifiers of Hedgehog Signaling in Drosophila melanogaster Identifies swm and mts Genetics, March 1, 2008; 178(3): 1399 - 1413. [Abstract] [Full Text] [PDF] J. Wu, X. Xiao, P. Zhao, G. Xue, Y. Zhu, X. Zhu, L. Zheng, Y. Zeng, and W. Huang Minicircle-IFN{gamma} Induces Antiproliferative and Antitumoral Effects in Human Nasopharyngeal Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4702 - 4713. [Abstract] [Full Text] [PDF] K.-i. Yamanaka, R. Clark, R. Dowgiert, D. Hurwitz, M. Shibata, B. E. Rich, K. Hirahara, D. A. Jones, S. Eapen, H. Mizutani, et al. Expression of Interleukin-18 and Caspase-1 in Cutaneous T-Cell Lymphoma Clin. Cancer Res., January 15, 2006; 12(2): 376 - 382. [Abstract] [Full Text] [PDF] B. Acres, M. Gantzer, C. Remy, N. Futin, N. Accart, O. Chaloin, J. Hoebeke, J.-M. Balloul, and S. Paul Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity Cancer Res., October 15, 2005; 65(20): 9536 - 9546. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020